Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Two phase 3 trials showed tirzepatide reduced obstructive sleep apnea severity and body weight over 52 weeks in adults with moderate-to-severe OSA and obesity.

Abstract

Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor.. Tirzepatide may be a potential treatment.. We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity.

Key Findings

Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. | The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. | The primary end point was the

Study Design

Randomized controlled trial